Literature DB >> 3107608

Phenotypic evolution of CTL B-lines in vitro.

M Février, C Foa, J Simonetti, C Prevot, M Barad, M Berebbi.   

Abstract

This study demonstrates that cytolytic T-cell lines exhibit progressive in-vitro modifications of their phenotype and of their growth behaviour and may use different pathways for their multiplication. Comparing three established cell lines, we firstly demonstrated that the expression of LFA-I is stable but the Lyt 2, 3 is rapidly lost. In this case, a high lectin-dependent cytotoxicity appears. Secondly, we demonstrated that two of the cell lines used the interleukin 2-interleukin 2 receptors (IL-2-IL-2R) binding pathway. Two different monoclonal antibodies showed that the IL-2 receptors distribution does not correlate with the number of functional sites which determines the IL-2 requirement. In contrast, the third cell line, although bearing high levels of IL-2 receptors, grows without the addition of IL-2; this cell growth is not inhibited by anti-IL-2 receptors monoclonal antibodies. Thirdly, it appears that the new property of IL-2 independence is associated with acquisition of the simultaneous capacity to induce tumour grafts in nude mice. As it has been recently reported that cytolytic T-lymphocytes against tumour cells could be promising immunotherapeutic agents, the spontaneous malignant transformation of such CTL lines should be taken into account before using them for adoptive immunotherapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107608      PMCID: PMC2013007     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  17 in total

Review 1.  The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy.

Authors:  E Kedar; D W Weiss
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

Review 2.  Cytotoxic T-lymphocytes. How do they function?

Authors:  G Berke
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

3.  Cytolytically active murine T-lymphocyte/polyoma virus-transformed fibroblast hybrids.

Authors:  M Berebbi; C Foa; E Imbert; I Fabre; C Lipcey
Journal:  Exp Cell Res       Date:  1983-05       Impact factor: 3.905

4.  Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex.

Authors:  T R Malek; R J Robb; E M Shevach
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

5.  Adoptive immunotherapy of cancer: accomplishments and prospects.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1984-01

6.  Thymoma production of T cell growth factor (Interleukin 2).

Authors:  J J Farrar; J Fuller-Farrar; P L Simon; M L Hilfiker; B M Stadler; W L Farrar
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

7.  Differential requirements for activation and growth of unprimed cytotoxic and helper T lymphocytes.

Authors:  M Gullberg; G Pobor; A Bandeira; E L Larsson; A Coutinho
Journal:  Eur J Immunol       Date:  1983-09       Impact factor: 5.532

8.  Failure of regulation of Tac antigen/TCGF receptor on adult T-cell leukemia cells by anti-Tac monoclonal antibody.

Authors:  M Tsudo; T Uchiyama; H Uchino; J Yodoi
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

9.  Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing.

Authors:  D Davignon; E Martz; T Reynolds; K Kürzinger; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen.

Authors:  R J Robb; W C Greene
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.